Education: The role of the first siderophore cephalosporin Fetcroja®(cefiderocol) in UK clinical practice: Introduction

Abid Hussain

doi:10.1093/jacamr/dlab051

Education: The role of the first siderophore cephalosporin Fetcroja^®(cefiderocol) in UK clinical practice: Introduction

Abid Hussain^*

^*Corresponding author for this work

Birmingham Lab

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Welcome to this special JAC-Antimicrobial Resistance Supplement, which is sponsored by Shionogi BV. The march of increasing Gram-negative resistance is relentless, and in the last 10 years we have seen a development in the pipeline of antimicrobials targeting the most resistant Gram-negative bacteria. Within this Supplement, we will present the current landscape for Gram-negative treatments, the launch data for cefiderocol, UK potential positioning and examples of early use.

Original language	English
Pages (from-to)	I3-I4
Journal	JAC-Antimicrobial Resistance
Volume	3
DOIs	https://doi.org/10.1093/jacamr/dlab051
Publication status	Published - 1 Jun 2021

Bibliographical note

Publisher Copyright:
© 2021 The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/jacamr/dlab051

Cite this

@article{0ba4a43653074b8db472b65fd1415ad8,

title = "Education: The role of the first siderophore cephalosporin Fetcroja{\textregistered}(cefiderocol) in UK clinical practice: Introduction",

abstract = "Welcome to this special JAC-Antimicrobial Resistance Supplement, which is sponsored by Shionogi BV. The march of increasing Gram-negative resistance is relentless, and in the last 10 years we have seen a development in the pipeline of antimicrobials targeting the most resistant Gram-negative bacteria. Within this Supplement, we will present the current landscape for Gram-negative treatments, the launch data for cefiderocol, UK potential positioning and examples of early use.",

author = "Abid Hussain",

note = "Publisher Copyright: {\textcopyright} 2021 The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.",

year = "2021",

month = jun,

day = "1",

doi = "10.1093/jacamr/dlab051",

language = "English",

volume = "3",

pages = "I3--I4",

journal = "JAC-Antimicrobial Resistance",

issn = "2632-1823",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Education

T2 - The role of the first siderophore cephalosporin Fetcroja®(cefiderocol) in UK clinical practice: Introduction

AU - Hussain, Abid

PY - 2021/6/1

Y1 - 2021/6/1

N2 - Welcome to this special JAC-Antimicrobial Resistance Supplement, which is sponsored by Shionogi BV. The march of increasing Gram-negative resistance is relentless, and in the last 10 years we have seen a development in the pipeline of antimicrobials targeting the most resistant Gram-negative bacteria. Within this Supplement, we will present the current landscape for Gram-negative treatments, the launch data for cefiderocol, UK potential positioning and examples of early use.

AB - Welcome to this special JAC-Antimicrobial Resistance Supplement, which is sponsored by Shionogi BV. The march of increasing Gram-negative resistance is relentless, and in the last 10 years we have seen a development in the pipeline of antimicrobials targeting the most resistant Gram-negative bacteria. Within this Supplement, we will present the current landscape for Gram-negative treatments, the launch data for cefiderocol, UK potential positioning and examples of early use.

UR - http://www.scopus.com/inward/record.url?scp=85135901637&partnerID=8YFLogxK

U2 - 10.1093/jacamr/dlab051

DO - 10.1093/jacamr/dlab051

M3 - Article

AN - SCOPUS:85135901637

SN - 2632-1823

VL - 3

SP - I3-I4

JO - JAC-Antimicrobial Resistance

JF - JAC-Antimicrobial Resistance

ER -